Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAF(V600E)-Specific Inhibitor)

Malignant melanoma is the most aggressive form of skin cancer and has a very low survival rate. Over 50% of melanomas harbor various BRAF mutations with the most common being the V600E. BRAF(V600E) mutation that causes constitutive activation of the MAPK pathway leading to drug-, immune-resistance,...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres-Collado, Antoni Xavier, Knott, Jeffrey, Jazirehi, Ali R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025215/
https://www.ncbi.nlm.nih.gov/pubmed/29795041
http://dx.doi.org/10.3390/cancers10060157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025215/
https://www.ncbi.nlm.nih.gov/pubmed/29795041
http://dx.doi.org/10.3390/cancers10060157

Ejemplares similares